Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

ClinicalTrials.gov ID: NCT01894958

Public ClinicalTrials.gov record NCT01894958. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.

Study identification

NCT ID
NCT01894958
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Enrollment
72 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years to 45 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2014 (Type not available)
Primary completion
Sep 2015 (Actual)
Completion
Oct 2015 (Actual)
Last update posted
Feb 5, 2018

2014 – 2015

United States locations

U.S. sites
17
U.S. states
16
U.S. cities
17
Facility City State ZIP Site status
UC Davis MIND Institute Sacramento California 95817 —
Children's Hospital Colorado Denver Colorado 80045 —
Children's National Hospital Washington D.C. District of Columbia 20010 —
Emory University Atlanta Georgia 30033 —
Rush University Medical Center Chicago Illinois 60612 —
Kennedy Krieger Institute Baltimore Maryland 21205 —
University of Massachusetts Medical School Worcester Massachusetts 01655 —
University of Michigan Ann Arbor Michigan 48109 —
University of Nebraska Omaha Nebraska 68588 —
Mount Sinai School of Medicine New York New York 10029 —
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229 —
Autism & Developmental Medicine Institute Geisinger Health System Lewisburg Pennsylvania 17837 —
Suburban Research Associates Media Pennsylvania 19063 —
Greenwood Genetic Center Greenwood South Carolina 29646 —
Vanderbilt University Medical Center Nashville Tennessee 37235 —
Texas Children's Hospital Houston Texas 77030 —
Seattle Children's Hospital Seattle Washington 98105 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01894958, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 5, 2018 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01894958 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →